Cleantech Transit Inc. (CLNO)
Scientists are busy developing different ways of converting biomass into a form that meets our energy needs, while making best use of the available energy. There are five different ways of extracting biomass energy: solid fuel combustion, gasification, pyrolysis, digestion and fermentation.
One source of biomass material is waste. Human society produces a veritable compost heap of organic waste. Kitchen scraps, sewage, the leftovers of the food processing industries, paper, sawdust, lawn clippings...the list is long. One of the reasons that energy from biomass is receiving so much attention is that it represents an opportunity to convert waste into something very valuable.
Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects that could maximize shareholder value. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech Transit Inc. has selected to invest in Phoenix Energy (www.phoenixenergy.net).
Cleantech Transit Inc recently reported the commencement of the final permitting prior to going online at Merced. The Merced project is a 500 Kilowatt biomass-generated power plant that is fully constructed, owned and operated by Phoenix Energy (www.phoenixenergy.net).The Merced project received permission for parallel testing to the grid. This testing process would allow Merced to connect to the grid on its own.
For more information about CLNO, visit www.cleantechtransitinc.com.
Power3 Medical Products, Inc., (PWRM.OB)
Certain changes in DNA can cause normal breast cells to become cancer. DNA is the chemical in each of our cells that makes up our genes -- the instructions for how our cells work. Some inherited DNA changes (mutations) can increase the risk for developing cancer and cause the cancers that run in some families. For instance, BRCA1 and BRCA2 are tumor suppressor genes -- they keep cancer tumors from forming. When they are changed (mutated), they no longer cause cells to die at the right time, and cancer is more likely to develop.
But most breast cancer DNA changes happen in single breast cells during a woman's life rather than having been inherited. So far, the causes of most of the DNA mutations that could lead to breast cancer are not known.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease).
Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro(R), a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials.
BC-SeraPro is a blood serum test designed to diagnose breast cancer in individuals. The test is based on proteomic technology in which a blood serum sample drawn from a patient will monitor the concentration of each protein biomarker residing in a panel of blood serum protein biomarkers to determine if a patient has breast cancer. The biomarkers in the panel have been selected for their ability to discriminate breast cancer patients from non-cancerous patients. Power3's statistical model evaluates the quantitative information of the protein biomarkers and automatically assigns a probability score. The probability score indicates to the physician that the patient "has cancer" or is "cancer-free". The score reflects how strongly the patient sample fits the biostatistical model and if the patient should be recommended for further follow-up by the clinician.
For more information please visit http://www.power3medical.com
QCR Holdings Inc. (Nasdaq:QCRH) announced that the Company's board of directors declared a cash dividend of $0.04 per share payable on July 7, 2011, to stockholders of record on June 23, 2011.
QCR Holdings, Inc., headquartered in Moline, Illinois, is a relationship-driven, multi-bank holding company, which serves the Quad City, Cedar Rapids, and Rockford communities through its wholly owned subsidiary banks.
Quad City Bank and Trust Company, which is based in Bettendorf, Iowa and commenced operations in 1994, Cedar Rapids Bank and Trust Company, which is based in Cedar Rapids, Iowa and commenced operations in 2001, and Rockford Bank and Trust Company, which is based in Rockford, Illinois and commenced operations in 2005, provide full-service commercial and consumer banking and trust and asset management services.
ADA-ES, Inc. (Nasdaq:ADES) announced financial results for the first quarter ended March 31, 2011. Total revenues increased 119% to $8.5 million. Gross margin was $7.2 million, or 85% of revenues, up from $1.4 million, or 35% of revenues, due to higher margins and revenues associated with Refined Coal. Operating income of $1.9 million, compared to an operating loss of $3.6 million in the first quarter of 2010. Net loss of $27.5 million, or $3.63 per diluted share, which included a $39.5 million expense related to the interim award in the Norit arbitration as well as associated $1.9 million of non-routine legal expenses, and a non-cash loss of $2.0 million from ADA's equity interest in ADA Carbon Solutions, LLC ("ADA-CS"). ADA would have reported net income after tax of $1.0 million or $0.14 per diluted share, excluding the above mentioned Norit award, legal expenses, the loss relating to its equity interest in ADA-CS and $14.9 million for the tax effect of such items.
ADA-ES, Inc. provides environmental technologies and specialty chemicals to the coal-burning utility industry in the United States. It engages in the development and marketing of refined coal technology for the control of nitrogen oxides and mercury; sale of equipment, field testing, and services related to mercury emission control for coal-fired boilers used in electric generation; research and development of carbon dioxide capture technology; and sale of flue gas conditioning equipment and chemicals, as well as other chemicals and technologies for coal-fired boilers.
Net 1 Ueps Technologies Inc. (Nasdaq:UEPS) announced results for the three and nine months ended March 31, 2011 ("3Q 2011"). Revenue for 3Q 2011 was $92.8 million, a year over year increase of 28% in US dollars ("USD") and 19% in constant currency. During 3Q 2011, net loss under US generally accepted accounting principles ("GAAP") was $21.6 million versus net income of $18.8 million for the three months ended March 31, 2010 ("3Q 2010"). GAAP loss per share for 3Q 2011 was $0.47 versus GAAP earnings per share of $0.41 a year ago. Fundamental earnings per share for 3Q 2011 was $0.38 compared to $0.51 for 3Q 2011, representing a decrease of 26% in USD and 31% in constant currency.
Net 1 UEPS Technologies, Inc. provides universal electronic payment system (UEPS) as an alternative payment system for the unbanked and under-banked populations in South Africa.
Sign up for free stock alerts at http://www.pennygovernance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyGovernance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyGovernance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(read more @ http://pennygovernance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) anticipates receiving 2,000,000 shares of 144 restricted stocks from the company for 12 months of advertisement services for Cleantech Transit, Inc. (CLNO.OB). Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).